Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 20/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591705 | 0.87 | P2RY12 (0.69) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL5141304 | 0.83 | P2RY12 (0.54) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL5334240 | 0.82 | P2RY12 (0.73) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL3590535 | 0.81 | P2RY12 (0.70) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL3586329 | 0.80 | P2RY12 (0.54) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL3591353 | 0.79 | P2RY12 (0.69) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL4005682 | 0.79 | P2RY12 (0.68) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL3589612 | 0.77 | P2RY12 (0.81) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL3585652 | 0.77 | P2RY12 (0.82) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL3587896 | 0.77 | P2RY12 (0.71) | P2RY12CYP3A4CYP2C9CHRM2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |